Quick facts about treatment with VYXEOS for sAML
Learn key facts, statistics, and benefits of treatment with VYXEOS (vix-e-ose).
Induction and consolidation with VYXEOS
In a clinical trial including older adults with t-AML or AML-MRC in which 153 people received VYXEOS and 156 people received the standard chemotherapya treatment for sAML
Approximately half of the patients treated with VYXEOS were alive at 9.6 months compared to 5.9 months for those treated with standard chemotherapy.a
Estimated survival at 1 year after the start of treatment was 42% for patients treated with VYXEOS compared to 28% for patients treated with standard chemotherapy.a
- Standard chemotherapy was cytarabine 100 mg/m2 and daunorubicin 60 mg/m2.
- Complete remission is the disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured.